Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: Winfastorlose who wrote (1368197)	7/23/2022 3:18:14 AM
From: Doren	Read Replies (2) \| Respond to of 1578245

> confirms NOPE. Apparently you, along with others making claims after NOT reading the studies, are CLEARLY unfit to be scientists. A real scientist would call you and the authors "sloppy" with data. I sure am glad MY doctor is qualified to be a doctor unlike quacks like this guy. The "Newstarget" article is a link to another site. Its an *opinion* piece. On the opinion piece it clearly says: " Data Availability Statement Not applicable." In other words there's no data to back it up. The author is a bullshitter. There was a link to the original article in Lancet... Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden Quotes from the article: The results STRENGTHEN the evidence-based rationale for administration of a THIRD VACCINE DOSE as a booster. Randomised clinical trials have shown a HIGH EFFICACY of the BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and ChAdOx1 nCoV-19 (Oxford-AstraZeneca) COVID-19 vaccines, and observational studies have estimated a HIGH REAL-WORLD EFFECTIVENESS. However, reports on breakthrough infections and waning immunity have raised concerns regarding the duration of protection.